Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
- Authors: Perez C.; Botta C.; Zabaleta A.; Puig N.; Cedena M.-T.; Goicoechea I.; Alameda D.; Jose-Eneriz E.S.; Merino J.; Rodriguez-Otero P.; Maia C.; Alignani D.; Maiso P.; Manrique I.; Lara-Astiaso D.; Vilas-Zornoza A.; Sarvide S.; Riillo C.; Rossi M.; Rosinol L.; Oriol A.; Blanchard M.-J.; Rios R.; Sureda A.; Martin J.; Martinez R.; Bargay J.; de la Rubia J.; Hernandez M.-T.; Martinez-Lopez J.; Orfao A.; Agirre X.; Prosper F.; Mateos M.-V.; Lahuerta J.-J.; Blade J.; San-Miguel J.F.; Paiva B.; Espinosa M.C.; Zamudio J.L.G.; Herranz E.R.; Tamayo R.R.; Sanchez J.M.; Bernal L.P.; Rodriguez A.P.G.; Garcia M.E.G.; Mayol A.S.; Lleonart J.B.; Suarez A.; Garcia M.T.H.; Gaisan C.M.; Ruiz B.H.; Montero F.C.; de Miguel Llorente D.; Ramos F.S.; Garcia A.I.; Manteca M.M.; Martin J.M.H.; Barrigon F.E.; Frade J.G.; de Coca A.G.; Franco C.A.; Gomez J.L.; Perez E.C.; Creixenti J.B.; Balari A.M.S.; Montes Y.G.; Teigell L.E.; Guinon A.G.; Monreal E.A.; Campos J.A.S.; Tutusaus J.M.M.; Rocafiguera A.O.; Gorrochategui M.G.; Mesa M.G.; Silva C.C.; Perez M.S.G.; Loureiro A.D.; Sanchez J.A.M.; Irazu M.J.N.; Parraga F.J.P.; Palacios J.J.L.; Barahona P.B.; Rodriguez C.E.; Rivas J.A.H.; de Oteyza J.P.; del Barrio R.I.; de la Guia A.L.; Amor A.A.; Pareja E.P.; Castello I.K.; Rodriguez M.J.B.; Martinez R.M.; Grau R.R.; Mesa E.G.; Sainz E.R.; de Arriba F.; Jimenez J.M.M.; Romera M.; Cardoso F.P.; Perez J.M.A.; Pomposo M.P.; Persona E.P.; Casasus A.I.T.; Garcia P.R.; Ramos I.J.; Lor M.B.V.; Garcia P.L.F.; Chamorro C.M.
- Publication year: 2020
- Type: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/513409
Abstract
Granulocytic myeloid-derived suppressor cells (G-MDSCs) promote tumor growth and immunosuppression in multiple myeloma (MM). However, their phenotype is not well established for accurate monitoring or clinical translation. We aimed to provide the phenotypic profile of G-MDSCs based on their prognostic significance in MM, immunosuppressive potential, and molecular program. The preestablished phenotype of G-MDSCs was evaluated in bone marrow samples from controls and MM patients using multidimensional flow cytometry; surprisingly, we found that CD11b1CD142CD151CD331HLADR2 cells overlapped with common eosinophils and neutrophils, which were not expanded in MM patients. Therefore, we relied on automated clustering to unbiasedly identify all granulocytic subsets in the tumor microenvironment: basophils, eosinophils, and immature, intermediate, and mature neutrophils. In a series of 267 newly diagnosed MM patients (GEM2012MENOS65 trial), only the frequency of mature neutrophils at diagnosis was significantly associated with patient outcome, and a high mature neutrophil/T-cell ratio resulted in inferior progression-free survival (P <.001). Upon fluorescence-activated cell sorting of each neutrophil subset, T-cell proliferation decreased in the presence of mature neutrophils (0.5-fold; P 5.016), and the cytotoxic potential of T cells engaged by a BCMA3CD3-bispecific antibody increased notably with the depletion of mature neutrophils (fourfold; P 5.0007). Most interestingly, RNA sequencing of the 3 subsets revealed that G-MDSC-related genes were specifically upregulated in mature neutrophils from MM patients vs controls because of differential chromatin accessibility. Taken together, our results establish a correlation between the clinical significance, immunosuppressive potential, and transcriptional network of well-defined neutrophil subsets, providing for the first time a set of optimal markers (CD11b/CD13/CD16) for accurate monitoring of G-MDSCs in MM.